Trial Profile
The clinical study of the safety and efficacy of denosumab for glucocorticoid-induced osteoporosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Corticosteroid-induced osteoporosis
- Focus Therapeutic Use
- 23 Mar 2021 Status changed from active, no longer recruiting to completed.
- 25 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Nov 2015 New trial record